Results 191 to 200 of about 54,207 (313)
A strange cause of chylothorax- Dasatinib induced
Journal of Association of Pulmonologist of Tamil Nadu, 2018 Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. Pulmonary side effects like pleural effusion due fluid retention are common.M Natraj, Dhanasekar, Irfan Ismail Ayub, Abdul Majeed Arshad, Rajagopalan, T Chandrasekar +5 moredoaj Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells [PDF]
, 2009 Christina S. Pichot, Sean M. Hartig, Liangping Xia, Constadina Arvanitis, D Monisvais, F. Y. Lee, Jeffrey A. Frost, Seth J. Corey +7 moreopenalex +1 more sourceDasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial [PDF]
, 2009 Jane F. Apperley, Jorge E. Cortés, Dong‐Wook Kim, Lydia Roy, Gail J. Roboz, Gianantonio Rosti, Eduardo Bullorsky, Elisabetta Abruzzese, Andreas Hochhaus, Dominik Heim, Cármino Antônio De Souza, Richard A. Larson, Jeffrey H. Lipton, H. Jean Khoury, Hyeoung-Joon Kim, Christian Sillaber, Timothy P. Hughes, Philipp Erben, Jan Van Tornout, Richard M. Stone +19 moreopenalex +1 more sourceSalt-inducible kinases (SIKs) regulate TGFβ-mediated transcriptional and apoptotic responses [PDF]
, 2020 A Rojas-Fernandez, A Woods, AR Ramjaun, AY Hsing, B Bierie, B Ozdamar, B-C Kim, BR Binder, C Allan, CJ David, CS Hill, DB Shackelford, EC Connolly, FA Ran, G Avery-Cooper, G Rena, G Rosti, GD Cuny, GJ Inman, GJ Inman, GM Keating, H Ikushima, J Massagué, J Massagué, J Massaous, J Ozanne, J Song, J Vogt, J Xu, JF Callahan, JL Wrana, JM Lizcano, Joan Massagué, JY Altarejos, K Clark, KA Brown, KJ Livak, LC Spender, LC Spender, M Abe, M Kowanetz, M Tojo, MO Li, MR Keeton, NJ Bright, P Lönn, PH Lin, PK Datta, PM Siegel, RJ Akhurst, RJ Akhurst, S DaCosta Byfield, S Dennler, S Edlund, S Strickson, SA Hawley, T Sonntag, TB Sundberg, Y Drabsch, Y Liu, Y Shi, Y Yang, Y Zhang, Y Zhang +63 morecore +2 more sourcesDasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase
Терапевтический архив, 2009 Aim. To analyse resistance to imatinib therapy, efficacy and safety of dasatinib.
Material and methods. A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage received dasatinib for 9-30 months (median 30 months) to September 2008.
Ol'ga Yur'evna Vinogradova, Anna Grigor'evna Turkina, Aleksandra Valer'evna Vorontsova, Ekaterina Yur'evna Chelysheva, Galina Anatol'evna Gusarova, S V Kuznetsov, Svetlana Rudol'fovna Goryacheva, Manana Aleksandrovna Sokolova, Evgeniy Mikhaylovich Abakumov, Ol'ga Veniaminovna Stakhina, Elena Vasil'evna Domracheva, Andrey Vital'evich Misyurin, Nina Dmitrievna Khoroshko, O Yu Vinogradova, A G Turkina, A V Vorontsova, E Yu Chelysheva, G A Gusarova, S V Kuznetsov, S R Goryacheva, M A Sokolova, E M Abakumov, O V Stakhina, E V Domracheva, A V Misyurin, N D Khoroshko +25 moredoaj Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells
, 2008 Yvonne Will, James A. Dykens, Sashi Nadanaciva, Brad Hirakawa, Joseph Jamieson, Lisa D. Marroquin, James T. Hynes, Shem Patyna, Bart Jessen +8 moreopenalex +1 more source